disufenton sodium (NXY 059)

a nitrone benzene bissulfonate in development for stroke; has neuroprotective activity; structure in first source

Also Known As:

NXY 059; Cerovive; HPN-07; NXY-059; NXY059; disodium 4-((tert-butylimino)-methyl)benzene-1,3-disulfonate N-oxide; disodium 4-((oxido-tert-butyl-azaniumylidene)methyl)benzene-1,3-disulfonate

Networked: 84 relevant articles (18 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzenesulfonates
        disufenton sodium: 84
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Arylsulfonic Acids
        Arylsulfonates: 1
        Benzenesulfonates
        disufenton sodium: 84

Experts

1.	Lapchak, Paul A: 7 articles (03/2011 - 05/2002)
2.	Ashwood, Tim: 7 articles (06/2008 - 12/2003)
3.	Green, A Richard: 7 articles (02/2006 - 11/2002)
4.	Cheng, Yi-Fang: 6 articles (12/2008 - 01/2005)
5.	Nilsson, Dag: 6 articles (12/2008 - 09/2006)
6.	Lees, Kennedy R: 6 articles (06/2008 - 01/2005)
7.	Shuaib, Ashfaq: 6 articles (06/2008 - 02/2006)
8.	Zivin, Justin A: 6 articles (02/2007 - 05/2002)
9.	Floyd, Robert A: 5 articles (01/2017 - 01/2004)
10.	Green, A R: 5 articles (12/2009 - 01/2001)

Related Diseases

1.	Stroke (Strokes) 03/01/2006 - "A recent analysis of one of the Phase III trials showed a statistically significant reduction in the primary outcome of disability after acute stroke in patients who received NXY-059 compared with placebo. " 05/16/2003 - "NXY-059 was the only compound to produce a major, statistically significant improvement in the motor deficit induced by the stroke. " 10/01/2008 - "The reported efficacy of NXY-059 in animal models of stroke is confounded by low study quality. " 10/01/2008 - "We report the impact of study quality on published estimates of the efficacy of NXY-059 in animal models of stroke. " 09/01/2013 - "This occurred during 1993-2006, when the 2,4-disulfonylphenyl PBN derivative, called NXY-059 in the stroke studies, was shown to be safe in humans and was taken all the way through clinical phase 3 trials and then was deemed to be ineffective. "
2.	Ischemic Stroke 02/09/2006 - "Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. " 02/09/2006 - "The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. " 06/01/2012 - "The nitrone-based compound NXY-059, which is the first drug to reach clinical trials for the treatment of acute ischemic stroke, has provided promise for the development of more robust pharmacological agents. " 10/19/2009 - "NXY-059, a polar compound with limited transport across the blood-brain barrier, has demonstrated neuroprotection in several animal models of acute ischemic stroke but failed to confirm clinical benefit in the second phase III trial (SAINT-II). " 12/01/2008 - "NXY-059 is no longer in development following a lack of efficacy found in a Phase III trial in patients with acute ischemic stroke. "
3.	Brain Ischemia (Cerebral Ischemia) 10/01/2008 - "We conducted a systematic review and stratified meta-analysis of published studies describing the efficacy of NXY-059 in experimental focal cerebral ischemia. " 08/03/2001 - "This study was designed to determine the effect of NXY-059 in a rodent model of permanent focal cerebral ischemia. " 01/01/2016 - "Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?" 01/01/2006 - "One of these agents, NXY-059, is effective in animal models of cerebral ischemia, and is in phase III clinical trials for ischemic stroke by AstraZeneca, under license from Renovis. " 08/03/2001 - "Our preliminary data demonstrate that administration of NXY-059 (60 mg/kg/h for 24 h) ameliorates cortical infarction in rats subjected to permanent focal cerebral ischemia with 24 h survival."
4.	Infarction (Infarctions) 10/01/2008 - "Overall, NXY-059 improved infarct volume by 43.3% (95% CI, 34.7 to 52.8). " 12/01/2003 - "The results showed that NXY-059 reduced infarct volume from 37.2% to 12.5% (p<0.0001). " 07/01/1999 - "This fact, and the pronounced antiischemic effect of NXY-059, suggest that the delayed events leading to infarction may be influenced by reactions occurring at the blood-endothelial interface." 08/03/2001 - "Our preliminary data demonstrate that administration of NXY-059 (60 mg/kg/h for 24 h) ameliorates cortical infarction in rats subjected to permanent focal cerebral ischemia with 24 h survival." 01/01/2002 - "Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window."
5.	Ischemia 03/01/2001 - "NXY-059 has neuroprotective efficacy when given 5 hours after onset of transient focal ischemia in the rat. " 11/15/2002 - "A recent in vivo study suggested that NXY-059 had poor brain uptake in a transient ischemia model. " 09/01/2003 - "NXY-059 has substantial protective effects when administered immediately after the onset of ischemia in a primate model of stroke. " 02/01/2003 - "NXY-059 was well tolerated in patients with an acute stroke at and above concentrations shown to be neuroprotective in an animal model when initiated 4 hours after onset of permanent focal ischemia." 11/15/2002 - "The permeability of [14C]NXY-059 increased 3.5 times after 9 h of hypoxia or 3 h of ischemia. "

Related Drugs and Biologics

1.	Free Radicals
2.	disufenton sodium (NXY 059)
3.	Neuroprotective Agents
4.	Oxides
5.	Factor VIIa (Activated Factor VII)
6.	Tenecteplase
7.	OKN 007
8.	TNK-tissue plasminogen activator
9.	Cytochromes c (Cytochrome c)
10.	nitrones

Related Therapies and Procedures

1.	Time-to-Treatment
2.	Therapeutics
3.	Intravenous Infusions
4.	Thrombolytic Therapy